HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.56 USD
-0.18 (-3.80%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.30 -0.26 (-5.70%) 4:18 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Brokerage Reports
HOOKIPA Pharma Inc. [HOOK]
Reports for Purchase
Showing records 1 - 20 ( 38 total )
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Positive ASCO Update Bolsters Our Confidence in HB-200; Higher PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
HB-200 Path Forward Well-Defined; New $5 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Next Clinical Catalyst Around the Corner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Hepatitis B Breakthrough Boom: Navigating a $450-$500 Billion Frontier
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
HB-200 Still the Focus, But HB-300 Also Intriguing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
ESMO Data Reinforce Our Confidence in HB-200?s HNSCC Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
HB-200?s HNSCC Front-Line Potential Validated; Adjust PT to $6.50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Catalyst-Rich 2023; Big Pharma Partnership Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Another Big Pharma Partnership Forged; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Key Clinical Update Remains on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Advancing HB-200 Into Earlier-Line Settings of HNSCC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Hookipa to Take the Baton For a Phase 1b HIV Study; Lower PT to $8; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Focus on Oncology Franchise; Lower PT to $15; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Clinical Updates Remain on Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
Initial HB-202/HB-201 Data is Premature to Call Off; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: HOOKIPA Pharma Inc.
Industry: Medical - Biomedical and Genetics
All Eyes on Updates on Oncology Program; Higher $21PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S